|
|
| | Vunakizumab Basic information |
| Product Name: | Vunakizumab | | Synonyms: | Vunakizumab;Research Grade Vunakizumab(DHH28804);Vunakizumab (anti-IL-17a);Research Grade Vunakizumab | | CAS: | 1792181-33-9 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Vunakizumab Structure]() |
| | Vunakizumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Vunakizumab Usage And Synthesis |
| Uses | Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis[1]. | | References | [1] Chunlei Zhang, et al. A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2022 Jul;87(1):95-102. DOI:10.1016/j.jaad.2022.01.005 |
| | Vunakizumab Preparation Products And Raw materials |
|